Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mirum Pharmaceuticals ( (MIRM) ) just unveiled an announcement.
On December 18, 2025, Mirum Pharmaceuticals entered into a subscription agreement with entities affiliated with institutional investor TCGX for a private placement of 1,000,000 common shares at $68.48 per share, raising approximately $68.5 million in gross proceeds in a transaction relying on private-offering exemptions from U.S. securities registration. Together with a separate $200 million private placement announced earlier in December, the new financing is intended to fund clinical development and commercial activities tied to Mirum’s proposed acquisition of Bluejay Therapeutics, a privately held biotech focused on viral and liver diseases, with both private placements and the Bluejay deal expected to close concurrently in the first quarter of 2026, subject to regulatory approvals and customary conditions, while Mirum has agreed to register the resale of the new shares for the investors after closing.
The most recent analyst rating on (MIRM) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
Mirum Pharmaceuticals shows promising revenue growth and strategic expansion through mergers, but faces challenges with profitability, high leverage, and a patent dispute. The technical indicators suggest bearish momentum, and the valuation reflects ongoing financial struggles.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals (Nasdaq: MIRM) is a leading rare disease drug developer with a global commercial footprint built around therapies for cholestatic and other overlooked liver and genetic conditions. Its marketed products include LIVMARLI for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile-acid synthesis disorders, and CTEXLI for cerebrotendinous xanthomatosis, while its pipeline features late-stage IBAT inhibitor volixibat for primary sclerosing cholangitis and primary biliary cholangitis and PDE4D inhibitor MRM-3379 for Fragile X syndrome.
Average Trading Volume: 666,357
Technical Sentiment Signal: Buy
Current Market Cap: $3.57B
For a thorough assessment of MIRM stock, go to TipRanks’ Stock Analysis page.